Investors Overview
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform drug technology optimized for solid tumor cancers that aims to achieve the CAR T like efficacy demonstrated in liquid tumors. The company is currently developing SYNC-T, a novel platform technology that uses a drug/device combination therapy. The platform is designed to achieve personalized T cell education, enabling the immune system to recognize and attack cancer throughout the body.  The first 2 candidates, SV-101 and SV-102 are currently in Phase 1 trials.
News & Press Releases
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Combination Immunotherapy Platform
Upcoming Events
The following are meetings and conferences that the Syncromune team plans to attend. If you would like to meet with one of our team members, please email us at info@syncromune.com
November 3 – 5, 2023
San Diego Convention Center
San Diego, CA
SOCIETY FOR IMMUNOTHERAPY OF CANCERS (SITC) ANNUAL MEETING
Meeting Information:Â https://www.sitcancer.org/2023/schedule/sitc23-annualmeeting
Join Us In The Fight Against Cancer
Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.
The information contained in our press releases and presentations should be considered accurate only as of the date it was originally issued. Syncromuneâ„¢ disavows any obligation to update the information contained in these press releases and presentations after the date of their issuance.